2104
C. PRAKASH, G. G. RAJESHWARAN, AND A. K. MOHANAKRISHNAN
(2.68 g, 13.10 mmol)], CuI (2.50 g, 13.10 mmol), TMSCl (0.80 mL, 6.30 mmol), and
Et3N (0.95 mL, 6.81 mmol) following the same procedure as that of 4 to afford crude
silyl-enol ether 12 (1.42 g, 84%) as a thick liquid. IR (KBr): 2174 (alkyne), 1616
1
(alkene) cmꢀ1. H NMR (400 MHz, CDCl3): d 4.39 (s, 1H, ꢀCH), 2.34–2.12 (m,
4H, ꢀCH2), 1.91–1.72 (m, 6H, ꢀCH2), 1.64–1.48 (m, 2H, ꢀCH2), 0.96 (s, 3H,
ꢀCH3), 0.18 (s, 9H, ꢀCH3), 0.13 (s, 9H, ꢀCH3). 13C NMR (125.7 MHz, CDCl3)
d 126.1, 116.3, 107.5, 85.1, 39.7, 37.5, 36.8, 31.8, 28.4, 26.2, 19.8, 15.2, 0.86, 0.22.
MS (EI) m=z (%): 322 (Mþ, 16), 307 (11), 226 (29), 198 (14), 158 (23), 73 (100). Crude
product 12 was used for the next step without further purification.
2-Bromo-3-methyl-3-(4-trimethylsilyl-3-butynyl)-1-cycloheptanone (13)
Bromination using compound 12 (1.30 g, 4.03 mmol), NaBr (415 mg,
4.03 mmol), and FeCl3 (1.31 g, 8.07 mmol) followed the same procedure as that of
5 to afford the bromo compound 13 (1.03 mg, 78%) as a yellow liquid. IR (KBr):
1
2173 (alkyne), 1706 (CO) cmꢀ1. H NMR (400 MHz, CDCl3): d 4.35 & 4.26 (2s,
1H, ꢀCH), 2.51–2.27 (m, 2H, ꢀCH2), 2.21–2.07 (m, 4H, ꢀCH2), 1.92–1.78 (m,
2H, ꢀCH2), 1.74–1.35 (m, 4H, ꢀCH2), 0.98 and 0.91 (2s, 3H, ꢀCH3), 0.16 and
0.12 (2s, 9H, ꢀCH3). 13C NMR (100 MHz, CDCl3): d 205.6, 204.8, 108.2, 107.3,
86.3, 85.2, 72.4, 71.7, 71.1, 70.3, 58.5, 54.3, 49.1, 43.2, 38.8, 30.6, 29.7, 28.6, 25.3,
22.2, 19.6, 19.0, 18.5, 17.6, 0.14, 0.09. MS (EI) m=z (%): 330 ([M þ 2]þ, 8), 328
(Mþ, 8), 304 (6), 231 (22), 193 (4), 153 (23), 73 (100).
(8aSꢃ)-Octahydro-8a-methyl-3-(trimethylsilyl)methylene)
azulen-4(5H)-one (14)
Radical cyclization of 13 (800 mg, 2.43 mmol) was performed using Bu3SnH
(1.1 mL, 3.65 mmol) and 1 M solution of Et3B in THF (2.15 mL, 3.65 mmol) follow-
ing the same procedure as that of 6 to afford bicyclic product 14 (347 mg, 57%) as a
.
viscous liquid. IR (film) 1701 (CO), 1613 (alkene) cmꢀ1 1H NMR (400 MHz,
CDCl3): d 5.63 & 5.26 (2s, 1H, ꢀCH), 3.54 & 3.30 (2s, 1H, ꢀCH), 2.42–2.38 (m,
4H, ꢀCH2), 1.72–1.59 (m, 6H, ꢀCH2), 1.48–1.45 (m, 2H, ꢀCH2), 1.07 (s, 3H,
ꢀCH2), 0.12 & 0.07 (2s, 9H, ꢀCH3). 13C NMR (100 MHz, CDCl3): d 212.3,
212.1, 160.0, 159.5, 123.9, 123.6, 70.9, 65.0, 45.5, 43.3, 42.3, 41.8, 39.3, 38.6, 37.7,
37.5, 34.5, 31.0, 27.5, 23.6, 22.6, 22.5, 19.3, 16.8, 0.36, 0.16. HRMS: calcd. for
C15H26OSi 250.1753; found 250.1762.
3-Methyl-3-(5-(trimethylsilyl)pent-4-ynyl)cycloheptanone (17)
Radical cyclization of 15 (750 mg, 2.19 mmol) was performed using Bu3SnH
(0.71 mL, 2.68 mmol) and 1 M solution of Et3B in THF following the same pro-
cedure as that of 6 to afford radical quenched product as a viscous liquid (0.35 g,
1
60%). IR (KBR): 2175 (alkyne), 1701 (CO) cmꢀ1. H NMR (400 MHz, CDCl3):
d 2.56–2.48 (m, 2H, ꢀCH2), 2.37–2.21 (m, 2H, ꢀCH2), 2.15–1.72 (m, 6H, ꢀCH2),
1.86–1.42 (m, 5H, ꢀCH2), 1.19 (s, 3H, ꢀCH3), 0.13 (s, 9H, ꢀCH3). 13C NMR
(100 MHz, CDCl3): d 210.2, 106.4, 85.3, 55.1, 46.7, 37.5, 34.2, 31.6, 27.5, 25.8,
24.1, 19.4, 15.8, 0.17. HRMS: calcd. for C16H28OSi 264.1909; found 264.1916.